Meet South Korea's No.1 Hugel Aesthetic Products on the Bluefarm Platform

BlueFarm Korea-Hugel Sign Distribution and Sales Agreement
Introducing Botox and Filler Products... Offering Discount Benefits

The pharmaceutical e-commerce platform 'BluePharm Korea' has signed a distribution and sales agreement with Hugel, the leading domestic company in botulinum toxin (Botox).

BlueMTech, which operates BluePharm Korea, announced on the 20th that it will exclusively distribute and sell Hugel's flagship products, including the botulinum toxin formulation 'Botulax' and the HA filler 'The Chaeum,' among other aesthetic products.

Botulax has led the market, holding the number one domestic market share for seven consecutive years since 2016. Through this agreement, Hugel plans to expand its distribution and sales channels to online platforms, further strengthening its competitiveness. BluePharm Korea will establish a dedicated aesthetic section and offer various benefits such as launch promotional events. The two companies will collaborate in various fields where IT can be integrated with the use of pharmaceuticals in hospitals and clinics.

Jung Byung-chan, CEO of BlueMTech, said, "The synergy between BluePharm Korea's hospital and clinic distribution network and IT services and Hugel's competitive products will create significant effects," adding, "We will also provide new innovations in the field of cosmetic surgery."

A Hugel representative stated, "We expect to strengthen our partnership by offering convenience and additional benefits through the IT platform to existing Hugel customers."

Meanwhile, BluePharm Korea is an online e-commerce platform exclusively for hospitals and clinics, with approximately 27,000 members. It is operated by BlueMTech, which was selected as a Baby Unicorn in 2021. The company plans to list on KOSDAQ in the second half of this year.

This content was produced with the assistance of AI translation services.